Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patients with advanced malignant melanoma and renal cell carcinoma. METHODS: In this multi-center phase I trial, cohorts of patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at 0.1, 0.3, 1, 3, 10, or 15 mg/kg on days 0, 28, 42, and 56. Patients achieving at least stable disease were eligible to receive Extended Treatment consisting of 4 doses of GC1008 every 2 weeks for up to 2 additional courses. Pharmacokinetic and exploratory biomarker assessments were performed. RESULTS: Twenty-nine patients, 28 with malignant melanoma and 1 with renal cell carcinoma, were enrolled and treated, 22 in the dose-escalation part and 7 in a safety cohort expansion. No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe. The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas (4 patients) and hyperkeratosis was the major adverse event observed. One malignant melanoma patient achieved a partial response, and six had stable disease with a median progression-free survival of 24 weeks for these 7 patients (range, 16.4-44.4 weeks). CONCLUSIONS: GC1008 had no dose-limiting toxicity up to 15 mg/kg. In patients with advanced malignant melanoma and renal cell carcinoma, multiple doses of GC1008 demonstrated acceptable safety and preliminary evidence of antitumor activity, warranting further studies of single agent and combination treatments. TRIAL REGISTRATION: Clinicaltrials.gov NCT00356460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fresolimumab, a human monoclonal antibody against TGF‐β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti‐tumor activity in malignant melanoma and renal cell carcinoma [42].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 4×
“Recently, targeted therapies directed against B-RAF and other genes have been used successfully to treat patients with MM [33].”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919 · cited 1×
“Transforming growth factor-beta (TGFb) is a pleiotropic cytokine that is a member of a superfamily of ligands that includes bone morphogenetic proteins and activins [1,2].”
BackgroundKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationTransforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · cited 2×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
Background
Cited by
Items 301–400 of 508
Epithelial-Mesenchymal Transition in Metastatic Colorectal Cancer
Morgado‐Díaz, J. A., Wagner, M. S., Squiavinato, A. C. M. S., de‐Freitas‐Junior, J. C. M., de Araújo, W. M., Tessmann, J. W., & Rocha, M. R. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-gastrointestinal-cancers-emt · Cited by 17
Shimizu, T., Powderly, J. D., Razak, A. A., LoRusso, P. M., Miller, K. D., Kao, S. C.-H., Kongpachith, S., Tribouley, C., Graham, M., Stoll, B. R., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1376551 · Cited by 16
Transforming Growth Factor‐β Pathway: Biological Functions and Therapeutic Targets
Mekky, R. H., Fetoh, M. E. A., Faheem, S. A., Radwan, A., Fawzy, M. H., Mustafa, A. M., Said, M. A., Călina, D. C., Sharifi‐Rad, J., & Cho, W. C. S. (2025) · MedComm · doi:10.1002/mco2.70278 · Cited by 17
Other targeted drugs in melanoma.
González‐Cao, M., Rodon, J. A., Karachaliou, N., Sanchez, J. M., Santarpía, M., Viteri, S., Pilotto, S., Teixidó, C., Riso, A. A., & Rosell, R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.12 · Cited by 16
“The development of reversible cutaneous keratoacanthomas/squamouscell carcinomas and hyperkeratosis was the major adverse event (95).”
BackgroundPharmacological and immunological targeting of tumor mesenchymalization
David, J. M., Dominguez, C. L., & Palena, C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.011 · Cited by 15
“The safety of this agentwas established in phase I trials for melanoma and renal cell carcinoma, in which multiple doses were generally well tolerated and no dose limiting toxicities reported (Morris et al., 2014).”
Zhou, C., Li, J., Lin, L., Shu, R., Dong, B., Cao, D., Li, Q., & Wang, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24562 · Cited by 16
“GC1008, a human monoclonal antibody, which can neutralize all three human isoforms of TGF-β, inhibited tumor progression with no dose-limiting toxicity [21].”
BackgroundMendoza, F. A., & Jiménez, S. A. (2021) · Rheumatology · doi:10.1093/rheumatology/keab762 · Cited by 16
Panneerpandian, P., & Ganesan, K. (2023) · Medical Oncology · doi:10.1007/s12032-023-01984-0 · Cited by 19
“Fresolimumab, a specific monoclonal antibody of TGF-β has been tested in advanced melanoma and renal cell carcinoma patients [32].”
BackgroundAngeli, E., Jordan, M., Otto, M., Stojanović, S. D., Karsdal, M. A., Bauersachs, J. K., Thum, T., Fiedler, J., & Genovese, F. (2024) · Matrix Biology · doi:10.1016/j.matbio.2024.02.008 · Cited by 15
Aberrant activation of TGF-β/ROCK1 enhances stemness during prostatic stromal hyperplasia
Li, Y., Li, J., Zhou, L. F., Wang, Z., Jin, L., Cao, J., Xie, H., & Wang, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01644-4 · Cited by 19
“For instance, fresolimumab, a human anti-TGF-β monoclonal antibody, has demonstrated efficacy against melanoma and renal cell activity in clinical trials, while pirfenidone can directly inhibit TGF-β production and alleviate pulmonary fibrosis [53, 54].”
BackgroundGenetic Signature of Human Pancreatic Cancer and Personalized Targeting
Reshkin, S. J., Cardone, R. A., & Koltai, T. (2024) · Cells · doi:10.3390/cells13070602 · Cited by 14
Takeuchi, H., Konnai, S., Maekawa, N., Takagi, S., Ohta, H., Sasaki, N., Kim, S., Okagawa, T., Suzuki, Y., Murata, S., et al. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.656715 · Cited by 14
“In a human phase I clinical trial, an anti-TGF-β antibody (GC1008) induced a partial response in one patient and stable disease in 6 of 28 patients with malignant melanoma and renal cell carcinoma (10).”
BackgroundTapia‐Galisteo, A., Sánchez-Rodríguez, I., Narbona, J., Iglesias-Hernández, P., Aragón-García, S., Jiménez-Reinoso, A., Compte, M., Khan, S. A., Tsuda, T., Chames, P., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2338558 · Cited by 15
“15 In general, results of TGF-β inhibitors as mono-therapy in cancer clinical trials have been inconsistent.”
BackgroundResultRole of exosomes in transforming growth factor-β-mediated cancer cell plasticity and drug resistance
Ruksha, T. G., & Palkina, N. V. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002322 · Cited by 16
Polaprezinc inhibits liver fibrosis and proliferation in hepatocellular carcinoma
Ye, J., Zhang, Z., Zhu, L. W., Lu, M., Li, Y., Zhou, J., Lu, X., & Du, Q. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7262 · Cited by 14
“Additionally, the anti‐human‐TGF‐β monoclonal antibody fresolimumab has been developed and is under clinical investigation for several malignancies (25,26).”
BackgroundNext Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
Mendoza, A., Álvarez, M., Maria, A. D., Margolin, K. A., Melero, I., & Ascierto, M. L. (2022) · Cells · doi:10.3390/cells11193147 · Cited by 15
Kim, N., Lee, J., Kim, S. H., Kang, S.-H., Bae, S., Yu, C.-H., Seo, J., & Kim, H.-T. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03777-4 · Cited by 15
Bone Marrow Osteoblast Damage by Chemotherapeutic Agents
Rellick, S. L., O’Leary, H. A., Piktel, D., Walton, C., Fortney, J. E., Akers, S. M., Martin, K. H., Denvir, J., Bošković, G., Primerano, D. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030758 · Cited by 14
Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations
Parchment, R. E., Voth, A. R., Doroshow, J. H., & Berzofsky, J. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.008 · Cited by 13
Self-citationSystemic sclerosis (scleroderma): remaining challenges
Connolly, M. K. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5449 · Cited by 14
Integrin β1 activation induces an anti-melanoma host response
Ritsma, L., Dey‐Guha, I., Talele, N. P., Solé, X., Salony, Chowdhury, J., Ross, K. N., & Ramaswamy, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175300 · Cited by 12
“Moreover, in an early clinical trial for metastatic melanoma patients, fresolimumab, an anti-TGF-β monoclonal antibody, resulted in mixed responses without clear overall benefit [20].”
BackgroundChikenji, T., Gingery, A., Zhao, C., Vanhees, M. K. D., Moriya, T., Reisdorf, R. L., An, K., & Amadio, P. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108312 · Cited by 13
TGF-β signaling pathways in cancers
Talar, B., & Czyż, M. (2013) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1068073 · Cited by 16
Modeling Macrophage Polarization and Its Effect on Cancer Treatment Success
Morales, V., & Soto-Ortiz, L. (2018) · Open Journal of Immunology · doi:10.4236/oji.2018.82004 · Cited by 12
“Monoclonal antibody Fresolimumab (anti-TGF-β) [43] 3 mg/kg every two weeks.”
BackgroundLi, S., Wu, X., Chen, P., Pei, Y., Zheng, K., Wang, W., Qiu, E., & Zhang, X. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000741 · Cited by 11
Molavand, M., Montazer, M., Ghareghomi, S., Yousefi, B., & Majidinia, M. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2519860 · Cited by 13
Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers
Dai, X., Thompson, E. W., & Ostrikov, K. (2022) · Biomolecules · doi:10.3390/biom12121880 · Cited by 13
Tokizaki, S., Podyma‐Inoue, K. A., Matsumoto, T., Takahashi, K., Kobayashi, M., Ibi, H., Uchida, S., Iwabuchi, S., Harada, H., Hashimoto, S., et al. (2023) · Cancer Science · doi:10.1111/cas.16006 · Cited by 14
“12 Although all approaches have been examined or are under investigation in clinical trials with various types of cancers, significant clinical outcomes have not been achieved thus far.”
BackgroundRose, A., Spender, L. C., Stephen, C., Mitchell, A., Rickaby, W., Bray, S. E., Evans, A. T., Dayal, J., Purdie, K. J., Harwood, C. A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24545 · Cited by 11
“This proposed role is supported by evidence from three human “models” of squamous skin tumours: a clear genotype-phenotype correlation between germline inactivating TGFBR1 mutations and families suffering from multiple self-healing squamous epithelioma (MSSE) [42], the presence of TGFBR1 mutations in sorafenibinduced…”
BackgroundLi, W., Tibben, M. M., Wang, Y., Lebre, M. C., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32568 · Cited by 14
In vivo imaging of TGFβ signalling components using positron emission tomography
Rotteveel, L., Poot, A. J., Bogaard, H. J., ten Dijke, P., Lammertsma, A. A., & Windhorst, A. D. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.08.011 · Cited by 11
TGF-β-mediated suppression of NK cell function and targeting strategies in tumor immunotherapy
Wang, B., & Bi, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105141 · Cited by 11
Roles of TGF-β in cancer hallmarks and emerging onco-therapeutic design
Dai, X., Hua, D., & Lu, X. (2022) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2022.37 · Cited by 12
Cirella, A., Bolaños, E., Luri‐Rey, C., Trani, C. A. D., Olivera, I., Gomis, G., Glez‐Vaz, J., Pinci, B., Garasa, S., Sánchez‐Gregorio, S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.07.026 · Cited by 10
“33 September 2023 humanized version of this mAb is in the clinic (fresolimumab) but has dose-limiting side effects.(41) Other forms of TGF-b antagonists such as TGF-bR inhibitors and TGF-b traps are also under clinical development via systemic delivery.”
BackgroundLiu, W., Nicol, L. E., & ORWOLL, E. S. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01188-2 · Cited by 10
“When used in advanced cancer trials, fresolimumab was associated with reversible cutaneous keratoacanthomas, squamous cell carcinomas and hyperkeratosis [31].”
Baranda, J. C., Robbrecht, D. G. J., Sullivan, R. J., Doger, B., Santoro, A., Barve, M. A., Grob, J., Bechter, O. E., Vieito, M., de Miguel, M. J., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13854 · Cited by 11
“12 The underlying mechanism for bleeding due to TGF β inhibition is unclear; moreover, bleeding could be multifactorial.”
BackgroundRecent advances in TGF-β signaling pathway in COVID-19 pathogenesis: A review
Majidpour, M., Azizi, S. G., Davodabadi, F., Akbar-Abad, M. S., Abdollahi, Z., Sargazi, S., & Shahriari, H. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107236 · Cited by 10
The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis
Amarante, M. K., de Oliveira, C. E. C., Ariza, C. B., Sakaguchi, A. Y., Ishibashi, C. M., & Watanabe, M. A. E. (2017) · International Reviews of Immunology · doi:10.1080/08830185.2017.1291639 · Cited by 11
“Besides its ambiguous scopes in cancer, recent investigations have boosted TGF-β pathway as a therapeutic target to treat tumors, in which TGF-β exerts strong immunosuppressive effects, such as malignant melanoma and renal cell carcinoma [57], glioblastoma [58], hepatocellular carcinoma [59], and malignant pleural mes…”
BackgroundLi, Z., Ma, J., Xu, M., Duan, Y., Huang, C., Dai, Q., & Yang, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115322 · Cited by 12
Receptor mimicking TGF-β1 binding peptide for targeting TGF-β1 signaling
Belair, D. G., Lee, J. S., Kellner, A. V., Huard, J., & Murphy, W. L. (2021) · Biomaterials Science · doi:10.1039/d0bm01374a · Cited by 9
Yuan, J., Jia, J., Wu, T., Zhi, D., Chen, Q., Zhang, J., Wu, Z., Yuan, Z. K., Zhao, X., Liu, J., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03076-5 · Cited by 9
Targeting Cytokines and Their Pathways for the Treatment of Cancer
Heimberger, A. B., Tripathi, S., & Platanias, L. C. (2023) · Cancers · doi:10.3390/cancers15215224 · Cited by 12
“An antibody that neutralized the isoforms of TGF-β was associated with reversible cutaneous keratoacanthomas and hyperkeratosis [50] and has not been further developed.”
BackgroundRiboflavin protects against pancreatic cancer metastasis by targeting TGF-β receptor 1
Zhao, J., Liu, X., Jin, X., Dong, T., Gao, X., Wang, J., Li, Y., & Ma, E. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107274 · Cited by 10
Maucort, C., Giorgio, A. D., Azoulay, S., & Duca, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000251 · Cited by 10
TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects
Agyemang, K., Johansen, A. M., Barker, G., Pennison, M. J., Sheffield, K., Jimenez, H., Blackman, C. F., Sharma, S., Asare, P. F., Singh, R. N., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00446-6 · Cited by 10
“2006 US Mixed 92 (80) 23 (20) 0 (0) 111 (85.”
Ma, L., Jiang, J., Qin, S., Chen, C., & Duan, Z. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00184 · Cited by 29
Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
Sinnberg, T. W., Niessner, H., Levesque, M. P., Dettweiler, C., Garbe, C., & Busch, C. (2018) · Biology Open · doi:10.1242/bio.032656 · Cited by 9
“Likewise, GC1008 (a human anti-TGF-βmonoclonal antibody that neutralizes all isoforms of TGF-β) had an acceptable safety profile and showed preliminary evidence of antitumor activity in pre-treated stage IV melanoma patients (Morris et al., 2014).”
BackgroundCancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer
Berzofsky, J. A., Wood, L. V., & Terabe, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.836906 · Cited by 9
Self-citationTargeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma
Kowalewski, A., Zdrenka, M., Grzanka, D., & Szylberg, Ł. (2020) · Cancers · doi:10.3390/cancers12113300 · Cited by 8
“Early phase Ib clinical trial (NCT00356460) investigated the use of a monoclonal antibody against TGF-β fresolimumab in RCC patients and showed preliminary evidence of antitumor activity [57].”
BackgroundDunai, C., Ames, E., Ochoa, M. C., Fernández-Sendin, M., Melero, I., Simonetta, F., Baker, J. B., & Álvarez, M. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.001 · Cited by 8
Ruan, Q., Lin, X., Wang, L., Wang, N., Zhao, Y., Wang, H., Tian, F., Hu, N., Li, Y., & Zhao, B. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114884 · Cited by 8
Quach, H. T., Hou, Z., Bellis, R. Y., Saini, J. K., Amador-Molina, A., Adusumilli, P. S., & Xiong, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152323 · Cited by 8
Targeted Therapies Against Growth Factor Signaling in Breast Cancer
Du, J., Yu, Y., Zhan, J., & Zhang, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_6 · Cited by 8
Fu, W., Wang, W., Li, H., Jiao, Y., Weng, J., Huo, R., Yan, Z., Wang, J., Xu, H., Wang, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.560211 · Cited by 10
Lin, C., Horwitz, M. E., & Rein, L. A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010204 · Cited by 8
“NK cells engineered with TGF-βR2 receptors carrying impaired downstream signaling have demonstrated enhanced cytotoxicity against certain solid tumors, though this has not yet been explored in the hematologic malignancies [158,159].”
Zhang, L., Zhang, X., Deng, X., Wang, P., Mo, Y., Zhang, Y., & Tong, X. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.10.050 · Cited by 8
Ding, X., Li, X., Chen, F., Wang, H., & Jiang, Y. (2025) · MedComm – Oncology · doi:10.1002/mog2.70023 · Cited by 9
Tang, L., Liu, S.-L., Yang, M., Wang, H., Zhou, Y., Yang, K., Li, Q., Hui, M. N., Chen, X., Leu, Y., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0085 · Cited by 7
Suresh, P. K., Banerjee, A., & Singh, P. (2023) · OpenNano · doi:10.1016/j.onano.2023.100134 · Cited by 8
Singh, N. K., Madan, R. A., & Gulley, J. L. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.754421 · Cited by 8
The role of innate immune cells in modulating vascular dynamics in skin malignancies
Marciniak, M., Stachowicz-Suhs, M., & Wagner, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189331 · Cited by 6
Molecular insights into the role of tumor-specific endothelial cells in metastasis
Taher, T. Z., Kheirkhah, A. H., Mehri, S., Mahmoudian, O., Atashi, S., & Kavianpour, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104964 · Cited by 8
Su, H., Fan, X., Nie, C., Tang, X., Hu, J., Xu, K., Zhang, L., & Ma, D. (2026) · Biomolecules · doi:10.3390/biom16010072 · Cited by 6
Mirala, F., Kashkooli, F. M., & Soltani, M. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104955 · Cited by 6
The prometastatic relevance of tumor‐infiltrating B lymphocytes in laryngeal squamous cell carcinoma
Missale, F., Bugatti, M., Marchi, F., Mandelli, G., Bruni, M., Palmerini, G., Monti, M., Bozzola, A. M., Arena, G., Guastini, L., et al. (2023) · Clinical & Translational Immunology · doi:10.1002/cti2.1445 · Cited by 6
“In contrast, the positive results obtained in the murine models targeting the TGFb pathway paved the way for the design of clinical trials in human solid tumors.(62,63) Despite the fact that several molecules targeting the TGFb pathway were designed and multiple trials conducted in the last 15 years, there is still no…”
ResultRole of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Murugaiyan, G. (2014) · Springer eBooks · doi:10.1007/978-3-662-44006-3_7 · Cited by 8
The application of antibody-based agents in cancer therapy based on their mechanisms of action
Qian, K., Li, G., Zhang, S., Zou, Y., Ai, H., Zheng, X., Fu, W., Lei, C., & Hu, S. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.02.021 · Cited by 6
“Fresolimumab, a humanized IgG4 monoclonal antibody exhibiting neutralization of all three isoforms of TGF-𝛽 , has exhibited promising outcomes in a phase I clinical trial [79] .”
Levitte, S., Khan, I., Iyahen, V., Ziai, J. M., Gubatan, J. M. B., Sheng, R., Glickstein, S. B., Sun, T., Park, K. T., McBride, J., et al. (2024) · Histochemistry and Cell Biology · doi:10.1007/s00418-024-02290-0 · Cited by 6
“…the TGFβ signaling cascade have shifted away from pan-TGFβ targeting because of adverse effects; fresolimumab, a humanized monoclonal antibody that binds all TGFβ isoforms, was associated with an array of serious adverse effects in patients with cancer who received the drug (Morris et al. 2014).”
Babiker, N. A., Nadeem, S., Kariem, H. A., Hameed, A. A., Negmeldin, A. T., & El‐labbad, E. M. (2025) · Pharmaceuticals · doi:10.3390/ph18050716 · Cited by 5
Yuan, S., Zhu, W., Wang, Y., & Yu, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s539571 · Cited by 6
“93 For receptor fusion proteins, SRK-181 is a TGFβ1-specific trap protein that blocks TGFβ1’s interaction with the receptor.”
Hall, M. H., Amobi, O., Khalaf, J., Afees, O. J., & Brantley, E. J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031510 · Cited by 6
Cho, H. J., Kwon, M., & Varner, J. A. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2944 · Cited by 11
Biphasic Role of TGF-β in Cancer Progression: From Tumor Suppressor to Tumor Promotor
Fan, C., Zhang, J., Hua, W., & ten Dijke, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64983-8 · Cited by 6
Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer
Garo, L. P., & Murugaiyan, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-30845-2_13 · Cited by 6
van Ravensteijn, S. G., Amir, A. L., Tauriello, D. V. F., van Herpen, C. M. L., Boers‐Sonderen, M. J., Wesseling-Rozendaal, Y. J. W., van Brussel, A., Keizer, D. M., Verheul, H. M. W., & Bol, K. F. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae108 · Cited by 5
“However, its effectiveness was limited, with an overall response rate of 3.5% in a study that included mostly patients with advanced melanoma [42].”
InfluentialShifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma
Zeng, Y., Rucki, A. A., Che, X., & Zheng, L. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.10.02 · Cited by 9
Laboratory biomarkers of an effective antitumor immune response. Clinical significance.
Malkova, A. M., Sharoyko, V. V., Zhukova, N. V., Gubal, A. R., & Орлова, Р. В. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100489 · Cited by 5
Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2
Ang, G. C. K., Gupta, A., Yap, S. X. L., Surana, U., & Taneja, R. (2022) · Cancers · doi:10.3390/cancers14122855 · Cited by 5
“For example, GC-1008, a pan monoclonal antibody, is able to neutralize all three TGF-β ligand isoforms and has been tested in clinical trials against renal cell carcinoma [200].”
BackgroundBelviso, I., Pastore, R., Mileo, A., Genio, E. D., Boccia, S., Palermi, S., Sellitto, C., & Motti, M. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136132 · Cited by 4
Inhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities
Gao, X., Li, X., Zhang, C., Zhou, J., Gu, K., Liu, X., & Bai, C. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157048 · Cited by 4
Drug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential
Shaik, R., Laddika, S. G., Unnisa, M., Hamza, A., Begum, S., & Sarwar, S. F. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00895-8 · Cited by 4
“Furthermore, mela - noma and renal cell carcinoma are among the tumors for which clinical trials have assessed fresolimumab, a human monoclonal antibody that neutralizes all three isoforms of TGF-β [ 47 ].”
Bakhtiari, M., Nickho, H., Mahmoudi, M., Arab, F. L., Hoseinzadeh, A., & Baharlou, R. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04389-x · Cited by 4
“…CAR systems incorporating extracellular TGF-β receptor domains linked to intracellular NKG2D signaling components, dominant-negative TGF-β receptors, and SMAD3 knockdown strategies, all of which enhance NK-cell resistance to TME-mediated suppression and improve antitumor activity [23, 236, 237].”
Liu, D., van der Zalm, A. P., Köster, J., Bootsma, S., Oyarce, C., van Laarhoven, H. W. M., & Bijlsma, M. F. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107315 · Cited by 4
Swati, S., Tripathi, S., Shree, B., Sengar, S., Mishra, A., & Sharma, V. (2025) · Scientific Reports · doi:10.1038/s41598-025-06934-6 · Cited by 4
Chen, X., Liu, D., Jin, J., Yao, H., Yao, S., Liu, Y., Sun, J., & Yang, Y. (2025) · Advanced Science · doi:10.1002/advs.202506827 · Cited by 6
Secretion of IL-6 and TGF-β2 by Colon Cancer Cells May Promote Resistance to Chemotherapy
Sritharan, S., & Sivalingam, N. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01247-3 · Cited by 4
Busschers, E., Chen, Y., Adeyeye, M., Song, I.-W., Busse, E., Castellon, A., Ruiz, O., Meyers, N., Bae, Y., Ambrose, C. G., et al. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf068 · Cited by 4
Farah, M., Nelson, K. C., Tetzlaff, M. T., Nagarajan, P., Torres-Cabala, C. A., Prieto, V. G., Curry, J. L., & Aung, P. P. (2020) · Journal of Cutaneous Pathology · doi:10.1111/cup.13645 · Cited by 4
“(10 of 29 patients) and de novo eruptive keratoacanthomas (4 patients).(11) Maculopapular rash was also reported in 4 of 7 patients with advanced hepatocellular carcinoma treated with the TGFBR-I inhibitor galunisertib plus sorafenib.”
BackgroundTowler, D. A. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304092 · Cited by 4
Epithelial-Mesenchymal Transition and Tumour Progression: An Overview
Al-Janabi, I. I. (2023) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v4i.99 · Cited by 3
Paneth cell: The missing link between obesity, MASH and portal hypertension
Kumar, M. S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102259 · Cited by 3
Alabi, F. A., Okpalanwaka, I. F., Oyegbesan, A., Okoyeocha, E. O. M., Oladejo, M., & Imodoye, S. O. (2025) · MedComm – Oncology · doi:10.1002/mog2.70027 · Cited by 9
Advanced cancer therapy: unlocking the potential of small molecule inhibitors
Sen, S., & Karati, D. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2571021 · Cited by 3
Converting ‘cold’ to ‘hot’ hepatocellular carcinoma for improved immunotherapy (Review)
Hsieh, C., & Chuang, P.-C. (2026) · Molecular Medicine Reports · doi:10.3892/mmr.2026.13803 · Cited by 3
“…such as galunisertib, a TgF‑ β receptor kinase inhibitor, or fresolimumab, an anti‑TgF‑ β antibody, have been investigated in patients with Hcc (83,84). although these agents have not yet been tested in phase iii trials in combi‑ nation with icis, preclinical analysis suggests that blocking TgF‑…”
The signal hijacker: How tumors co-opt chemical, electrical, and mechanical cues to thrive
Wang, Y.-F., Wang, S.-Y., He, Z.-Y., Jin, M.-Z., Yuan, W.-Z., & Jin, W.-L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189556 · Cited by 3
Targeting dormant cancer cells: ferroptosis as a precision therapeutic strategy
Hao, S., Guo, Y., Huang, Q., Gan, L., Chen, C., Li, Q., Di, C., & Si, J. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00895-y · Cited by 3
“In vivo [ In vivo [209] TGF-β1 Fresolimumab A human anti-TGF-β monoclonal antibody targeting TGF-β1, 2, and 3 Phase II clinical trial [210] Table 2 Precision inhibitors and agonists directed at critical signaling nodes studies have begun encapsulating agents such as RSL3 and ML210 into nanocarriers…”
Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology
Valcz, G., Sípos, F., Tulassay, Z., Molnar, B. A., & Yagi, Y. (2015) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-202561rep · Cited by 3
Tumor microenvironment as a target of malignant gliomas treatment
Borisov, K. E., & Дамировна, С. Д. (2015) · Malignant tumours · doi:10.18027/2224-5057-2015-4-14-23 · Cited by 3
JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4
Du, J., Wang, J., Ge, F., Ma, H., Hongdao, Z. H. U., Du, J., Yan, F., He, Q., Yang, B., Yuan, T., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116748 · Cited by 4
Carreira, V., Standeven, A. M., Jing, Y., Hardisty, J. F., Cohen, S. M., Kerns, W., & Snook, S. S. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfaa190 · Cited by 3
Metadata
- Authors
- Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P.
- Affiliations
- National Cancer Institute (US)
- Rutgers Cancer Institute (US)
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Morris, John C.
- Berzofsky, Jay A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-11
- Volume
- 9
- Issue
- 3
- Pages
- e90353
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3949712
- OpenAlex
- W2075873658
- Cited by
- 487
- References
- 50
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 48 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 49 · 2019: 30 · 2018: 29 · 2017: 41 · 2016: 30 · 2015: 29 · 2014: 9
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- Ohio State University
- Rutgers Cancer Institute of New Jersey
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- TGF-beta, melanoma, renal cell carcinoma, advanced cancer, dose escalation, safety, pharmacokinetics, keratoacanthoma, squamous cell carcinoma, anticancer activity, progression-free survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Staging, Tomography, X-Ray Computed, Transforming Growth Factor beta, Treatment Outcome, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.